Legal & General Group
TSHA icon

Legal & General Group’s Taysha Gene Therapies TSHA Stock Holding History

Legal & General Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$737K Buy
108,207
+3,899
+4% +$23.1K ﹤0.01% 2287
2026
Q1 		$466K Sell
104,308
-28,838
-22% -$134K ﹤0.01% 2369
2025
Q4 		$732K Buy
133,146
+109,997
+475% +$534K ﹤0.01% 2307
2025
Q3 		$75.7K Buy
23,149
+4,754
+26% +$13.5K ﹤0.01% 2664
2025
Q2 		$42.5K Sell
18,395
-1,563
-8% -$3.4K ﹤0.01% 2744
2025
Q1 		$27.7K Sell
19,958
-60
-0.3% -$100 ﹤0.01% 2833
2024
Q4 		$34.6K Hold
20,018
– – ﹤0.01% 2852
2024
Q3 		$40.2K Buy
20,018
+2,093
+12% +$4.59K ﹤0.01% 2828
2024
Q2 		$40.2K Buy
+17,925
New +$52.2K ﹤0.01% 2824
2022
Q2 		– Sell
-16,100
Closed -$104K – 3656
2022
Q1 		$104K Hold
16,100
– – ﹤0.01% 2852
2021
Q4 		$187K Buy
16,100
+8,993
+127% +$136K ﹤0.01% 2747
2021
Q3 		$132K Buy
7,107
+3,358
+90% +$63.8K ﹤0.01% 2793
2021
Q2 		$80K Buy
3,749
+2,835
+310% +$65.3K ﹤0.01% 2806
2021
Q1 		$18K Hold
914
– – ﹤0.01% 3178
2020
Q4 		$24K Buy
914
+14
+2% +$302 ﹤0.01% 3024
2020
Q3 		$20K Buy
+900
New +$21.2K ﹤0.01% 2973

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Legal & General Group's TSHA Position: Q2 2026 in Review

Legal & General Group increased its Taysha Gene Therapies (TSHA) stake by 3.7% in Q2 2026, buying an estimated $23.1K and bringing the position to 108,207 shares worth $737K. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Legal & General Group first reported a position in TSHA in Q3 2020 and has held it in 16 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Legal & General Group held 108,207 shares of Taysha Gene Therapies worth $737K as of Q2 2026.
  • Legal & General Group bought 3,899 Taysha Gene Therapies shares in Q2 2026, an estimated $23.1K.
  • Taysha Gene Therapies made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2287 holding.
  • Legal & General Group first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 16 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.